STOCK TITAN

Xcelerate, Inc. Announces That It Has Filed Its 2023 Annual Report

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Xcelerate, Inc. announced the filing of its 2023 Annual Report, reporting audited financial results for the year. The company achieved its first revenue year in history, marking significant milestones and progress towards growth. Revenues from the majority interest in ESN Group are set to increase in 2024 due to new contracts.

Xcelerate, Inc. ha annunciato la presentazione del suo Rapporto Annuale 2023, rivelando i risultati finanziari auditati dell'anno. La società ha raggiunto il suo primo anno di entrate nella storia, segnando traguardi importanti e progressi verso la crescita. Si prevede un aumento delle entrate provenienti dalla maggioranza degli interessi nel Gruppo ESN nel 2024 a causa di nuovi contratti.
Xcelerate, Inc. anunció la presentación de su Informe Anual 2023, reportando los resultados financieros auditados del año. La compañía logró su primer año de ingresos en la historia, marcando hitos significativos y avances hacia el crecimiento. Se espera que los ingresos de la mayoría de interés en el Grupo ESN aumenten en 2024 debido a nuevos contratos.
Xcelerate, Inc.는 2023년 연차보고서를 공시하며 그 해의 감사된 재무 결과를 보고했습니다. 회사는 역사상 첫 매출 해를 달성하며 중요한 이정표와 성장을 향한 진전을 기록했습니다. ESN 그룹의 다수 이해관계로부터의 수익이 2024년에 새로운 계약으로 인해 증가할 것으로 예상됩니다.
Xcelerate, Inc. a annoncé le dépôt de son Rapport Annuel 2023, rapportant les résultats financiers audités de l'année. L'entreprise a réalisé sa première année de revenus dans l'histoire, marquant des jalons importants et des progrès vers la croissance. Les revenus issus de l'intérêt majoritaire dans le Groupe ESN devraient augmenter en 2024 en raison de nouveaux contrats.
Xcelerate, Inc. hat die Einreichung seines Jahresberichts 2023 bekannt gegeben, der die geprüften Finanzergebnisse des Jahres darlegt. Das Unternehmen erreichte das erste Umsatzjahr seiner Geschichte und markierte bedeutende Meilensteine und Fortschritte im Wachstum. Es wird erwartet, dass die Einnahmen aus dem mehrheitlichen Interesse an der ESN-Gruppe im Jahr 2024 durch neue Verträge steigen werden.
Positive
  • Achieved the first revenue year in Xcelerate, Inc. history

  • Milestones and progress towards growth in 2023

  • Increase in revenues expected in 2024 from new contracts

Negative
  • None.

MAULDIN, SC / ACCESSWIRE / April 30, 2024 / Xcelerate, Inc. (OTCQB:XCRT) today reported its audited financial results for the year ended December 31, 2023. The Company's Annual Report on Form 1-K has been filed with the U.S. Securities and Exchange Commission ("SEC") and may be viewed on the Electronic Document Gathering and Retrieval System ("EDGAR") at www.sec.gov/edgar , and on the Company's website at www.xcelerate.global .

Mike O'Shea, Xcelerate's CEO said "We entered 2023 poised for what we anticipated would be the first revenue year in Xcelerate, Inc. history and today I am happy to announce that we have achieved that goal. 2023 marked Xcelerate's achievement of key milestones and progress toward its next phase of growth. These revenues represent those generated by our majority interest in ESN Group and are representative only from July 2023, when we acquired that interest. We are expecting to increase revenues significantly in 2024 as a result of the recently announced addition of ESN's contract with "AFFES" (Army & Air Force Exchange Service) and commencement of our operations with the two hospital contracts that Afiya Sasa holds in Tanzania."

Investors and stakeholders are encouraged to stay updated on the latest developments by visiting the Company's website at https://xcelerate.global/.

ABOUT XCELERATE INC.
Since establishing new management and adopting a new business plan in May 2020, we have developed three separate but related businesses within the medical, health and wellness sectors, including (i) formulation, packaging and marketing of consumer health and beauty, clinically tested skin care products; (ii) development of AI and virtual health technology to assist patients in developing countries, initially in Africa, to provide for their population to obtain medical care by extending the reach of physicians through the use of that technology; and (iii) owning and licensing the rights to various forms of medical equipment and portfolio of patents, patents pending and technology licenses. We believe we have made significant advances in the businesses included in (i) and (ii) and while no assurances can be provided, believe we are on the cusp of significant growth. For more information visit www.xcelerate.global or contact us at 854-900-2020 or email info@xcelerate.global.

SAFE HARBOR
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting the Company's financial condition or results of operations; (iii) the Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.

SOURCE: Xcelerate, Inc.



View the original press release on accesswire.com

Xcelerate Inc.

OTC:XCRT

XCRT Rankings

XCRT Latest News

XCRT Stock Data

572.82k
245.12M
41.61%
Dental Laboratories
Manufacturing
Link
United States of America
Mauldin